Spending on advertising for drugs targeting obesity and diabetes is skyrocketing this year, with drug manufacturers dedicating close to $500 million to these promotions.
In the United States, pharmaceutical companies have significantly increased their advertising spending on obesity and diabetes treatments, reaching nearly $500 million in the first seven months of this year, marking a 20% rise compared to the same period last year. This data, sourced from advertising analytics firm MediaRadar, underscores the competitive rush among companies to…
